Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2019 Filed May 17, 2019 18:00 UTC |
Noble JamesDirector · Chief Executive Officer
|
Exercise / conversionOrdinary Shares with a nominal value of GBP0.001 per share | 1,773,100 | $0.14 | $253,553.30 |
DisclosureSEC source: 0001104659-19-030337 · a4.xml · nonDerivative · entry 1 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,773,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person. F2 · price: The price reported in Column 4 of $0.143 per ordinary share is derived from the option purchase price paid on May 16, 2019 of GBP 0.112 per ordinary share. F1 · balance_after: The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 02:31 UTC |
Amado RafaelPresident, R & D
|
SaleAmerican Depositary Shares representing Ordinary Shares | 3,028 | $5.37 | $16,258.54 |
DisclosureSEC source: 0001104659-19-002164 · a4.xml · nonDerivative · entry 1 Amado Rafael · CIK 0001662119 · President, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,974 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 16,000 ADSs and RSU-style options and other options covering an aggregate of 9,526,608 ordinary shares of the Issuer. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:31 UTC |
Binder-Scholl Gwendolyn KnowltonChief Technology Officer
|
SaleAmerican Depositary Shares representing Ordinary Shares | 1,514 | $5.37 | $8,129.27 |
DisclosureSEC source: 0001104659-19-002166 · a4.xml · nonDerivative · entry 1 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,487 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 4,979,951 ordinary shares of the Issuer. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 02:31 UTC |
Bertrand William C JRChief Operating Officer
|
SaleAmerican Depositary Shares representing Ordinary Shares | 2,271 | $5.37 | $12,193.91 |
DisclosureSEC source: 0001104659-19-002165 · a4.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 5,391,864 ordinary shares of the Issuer. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 02:30 UTC |
Rawcliffe AdrianChief Financial Officer
|
SaleAmerican Depositary Shares representing Ordinary Shares | 3,084 | $5.37 | $16,559.23 |
DisclosureSEC source: 0001104659-19-002163 · a4.xml · nonDerivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,318 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 8,354,784 ordinary shares of the Issuer. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC |
Amado RafaelPresident, R & D
|
GrantOption to purchase Ordinary Shares · Derivative | 224,724 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-001301 · a4.xml · derivative · entry 2 Amado Rafael · CIK 0001662119 · President, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,724 Underlying: Ordinary Shares · 224,724 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022 and 56,190 Ordinary Shares on January 4, 2023. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC |
Amado RafaelPresident, R & D
|
GrantOption to purchase Ordinary Shares · Derivative | 1,006,224 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-19-001301 · a4.xml · derivative · entry 1 Amado Rafael · CIK 0001662119 · President, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,224 Underlying: Ordinary Shares · 1,006,224 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 21,138 Ordinary Shares on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:02 UTC |
Bertrand William C JRChief Operating Officer
|
GrantOption to purchase Ordinary Shares · Derivative | 224,724 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-001304 · a4.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,724 Underlying: Ordinary Shares · 224,724 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022 and 56,190 Ordinary Shares on January 4, 2023. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:02 UTC |
Bertrand William C JRChief Operating Officer
|
GrantOption to purchase Ordinary Shares · Derivative | 1,006,224 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-19-001304 · a4.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,224 Underlying: Ordinary Shares · 1,006,224 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 21,138 Ordinary Shares on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:00 UTC |
Noble JamesDirector · Chief Executive Officer
|
GrantOption to purchase Ordinary Shares · Derivative | 561,792 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-001300 · a4.xml · derivative · entry 2 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,792 Underlying: Ordinary Shares · 561,792 shares Expires 2029-01-04 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 140,448 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 140,448 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:00 UTC |
Noble JamesDirector · Chief Executive Officer
|
GrantOption to purchase Ordinary Shares · Derivative | 2,515,536 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-19-001300 · a4.xml · derivative · entry 1 Noble James · CIK 0001388000 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,515,536 Underlying: Ordinary Shares · 2,515,536 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 628,884 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 52,404 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 52,512 Ordinary Shares on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC |
Rawcliffe AdrianChief Financial Officer
|
GrantOption to purchase Ordinary Shares · Derivative | 280,896 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-001302 · a4.xml · derivative · entry 2 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,896 Underlying: Ordinary Shares · 280,896 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 70,224 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on the fourth of each January from January 4, 2021 through January 4, 2023. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC |
Rawcliffe AdrianChief Financial Officer
|
GrantOption to purchase Ordinary Shares · Derivative | 1,257,744 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-19-001302 · a4.xml · derivative · entry 1 Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,744 Underlying: Ordinary Shares · 1,257,744 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 314,436 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 26,238 Ordinary Shares on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC |
TAYTON-MARTIN HELEN KATRINAChief Business Officer
|
GrantOption to purchase Ordinary Shares · Derivative | 224,724 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-001303 · a4.xml · derivative · entry 2 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,724 Underlying: Ordinary Shares · 224,724 shares Expires 2029-01-04 F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022, and 56,190 Ordinary Shares on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 02:01 UTC |
TAYTON-MARTIN HELEN KATRINAChief Business Officer
|
GrantOption to purchase Ordinary Shares · Derivative | 1,006,224 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001104659-19-001303 · a4.xml · derivative · entry 1 TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,224 Underlying: Ordinary Shares · 1,006,224 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 2, 2022 and 21,138 Ordinary Shares on January 4, 2023. Read SEC document |
| December 17, 2018 Filed Dec 20, 2018 01:04 UTC |
Alleva Lawrence MDirector
|
PurchaseOrdinary Shares with a nominal value of GBP0.001 per share | 47,280 | $0.84 | $39,715.20 |
DisclosureSEC source: 0001104659-18-073869 · a4.xml · nonDerivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Trust Disclosed balance after: 47,280 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. F2 · shares: The 47,280 ordinary shares reported in Column 4 and Column 5 are represented by 7,880 ADSs. F3 · price: The price reported in Column 4 of $0.84 per ordinary share is derived from the purchase price paid on December 17, 2018 of $5.006 per ADS divided by six. F2 · balance_after: The 47,280 ordinary shares reported in Column 4 and Column 5 are represented by 7,880 ADSs. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:58 UTC |
Binder-Scholl Gwendolyn KnowltonChief Technology Officer
|
SaleAmerican Depositary Shares | 25,000 | $13.79 | $344,750.00 |
DisclosureSEC source: 0001104659-18-060128 · a4.xml · nonDerivative · entry 1 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ordinary shares were obtained from the exercise of share options granted on March 20, 2015. The exercise of share options and the sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $13.54 to $13.995, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:46 UTC |
BARRIS PETER J10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 12,000,000 | $1.67 | $20,000,400.00 |
DisclosureSEC source: 0001209191-18-050281 · doc4.xml · nonDerivative · entry 2 BARRIS PETER J · CIK 0001005561 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 5 Disclosed balance after: 12,000,000 F4 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F4 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F4 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F5 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:46 UTC |
BARRIS PETER J10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050281 · doc4.xml · nonDerivative · entry 1 BARRIS PETER J · CIK 0001005561 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:49 UTC |
Viswanathan Ravi10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 12,000,000 | $1.67 | $20,000,400.00 |
DisclosureSEC source: 0001209191-18-050293 · doc4.xml · nonDerivative · entry 2 Viswanathan Ravi · CIK 0001479386 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 5 Disclosed balance after: 12,000,000 F4 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F4 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F4 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F5 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:49 UTC |
Viswanathan Ravi10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050293 · doc4.xml · nonDerivative · entry 1 Viswanathan Ravi · CIK 0001479386 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:49 UTC |
SANDELL SCOTT D10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 12,000,000 | $1.67 | $20,000,400.00 |
DisclosureSEC source: 0001209191-18-050291 · doc4.xml · nonDerivative · entry 2 SANDELL SCOTT D · CIK 0001237289 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 5 Disclosed balance after: 12,000,000 F4 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F4 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F4 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F5 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:49 UTC |
SANDELL SCOTT D10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050291 · doc4.xml · nonDerivative · entry 1 SANDELL SCOTT D · CIK 0001237289 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:48 UTC |
KERINS PATRICK J10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050286 · doc4.xml · nonDerivative · entry 1 KERINS PATRICK J · CIK 0001235112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:45 UTC |
BARRETT M JAMES10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050280 · doc4.xml · nonDerivative · entry 1 BARRETT M JAMES · CIK 0001219855 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:48 UTC |
MOTT DAVID MDirector · 10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 12,000,000 | $1.67 | $20,000,400.00 |
DisclosureSEC source: 0001209191-18-050288 · doc4.xml · nonDerivative · entry 2 MOTT DAVID M · CIK 0001219871 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 5 Disclosed balance after: 12,000,000 F4 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F4 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F4 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F5 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:48 UTC |
MOTT DAVID MDirector · 10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050288 · doc4.xml · nonDerivative · entry 1 MOTT DAVID M · CIK 0001219871 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:46 UTC |
BASKETT FOREST10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 12,000,000 | $1.67 | $20,000,400.00 |
DisclosureSEC source: 0001209191-18-050282 · doc4.xml · nonDerivative · entry 2 BASKETT FOREST · CIK 0001277631 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 5 Disclosed balance after: 12,000,000 F4 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F4 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F4 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F5 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:46 UTC |
BASKETT FOREST10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050282 · doc4.xml · nonDerivative · entry 1 BASKETT FOREST · CIK 0001277631 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:45 UTC |
New Enterprise Associates 14, L.P.10% owner
NEA Partners 14, L.P.10% owner
NEA 14 GP, LTD10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050279 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.direct: The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:49 UTC |
Sonsini Peter W.10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 12,000,000 | $1.67 | $20,000,400.00 |
DisclosureSEC source: 0001209191-18-050292 · doc4.xml · nonDerivative · entry 2 Sonsini Peter W. · CIK 0001559807 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 5 Disclosed balance after: 12,000,000 F4 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F4 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F4 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F5 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:49 UTC |
Sonsini Peter W.10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050292 · doc4.xml · nonDerivative · entry 1 Sonsini Peter W. · CIK 0001559807 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:47 UTC |
Florence Anthony A. Jr.10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 12,000,000 | $1.67 | $20,000,400.00 |
DisclosureSEC source: 0001209191-18-050284 · doc4.xml · nonDerivative · entry 2 Florence Anthony A. Jr. · CIK 0001559827 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 5 Disclosed balance after: 12,000,000 F4 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F4 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F4 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F5 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:47 UTC |
Florence Anthony A. Jr.10% owner
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 3,000,000 | $1.67 | $5,000,100.00 |
DisclosureSEC source: 0001209191-18-050284 · doc4.xml · nonDerivative · entry 1 Florence Anthony A. Jr. · CIK 0001559827 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 82,978,668 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Reporting Person has no pecuniary interest. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:47 UTC |
Behbahani AliDirector
|
PurchaseOrdinary Shares with a nominal value of 0.001 GBP per share | 12,000,000 | $1.67 | $20,000,400.00 |
DisclosureSEC source: 0001209191-18-050283 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 3 Disclosed balance after: 12,000,000 F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2 · price: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F3 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 20:02 UTC |
Binder-Scholl Gwendolyn KnowltonChief Technology Officer
|
SaleAmerican Depositary Shares | 25,000 | $10.25 | $256,250.00 |
DisclosureSEC source: 0001104659-18-054853 · a4.xml · nonDerivative · entry 1 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ordinary shares were obtained from the exercise of share options granted on March 20, 2015. The exercise of share options and the sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $10.15 to $10.41, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 21:14 UTC |
Amado RafaelPresident, R & D
|
GrantOption to purchase Ordinary Shares · Derivative | 678,720 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-050188 · a4.xml · derivative · entry 1 Amado Rafael · CIK 0001662119 · President, R & D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,720 Underlying: Ordinary Shares · 678,720 shares Expires not disclosed F1 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.29679 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 169,680 Ordinary Shares on August 6, 2019 and will be exercisable as to the remainder in annual installments of 169,680 Ordinary Shares on the sixth of each August from August 6, 2020 through August 6, 2022. F3 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:01 UTC |
Zaks Tal ZviDirector
|
GrantOption to purchase Ordinary Shares · Derivative | 124,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-18-042322 · a4.xml · derivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Ordinary Shares · 124,000 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 17:00 UTC |
Kerr Giles Francis BertramDirector
|
GrantOption to purchase Ordinary Shares · Derivative | 124,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-18-042321 · a4.xml · derivative · entry 1 Kerr Giles Francis Bertram · CIK 0001689112 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Ordinary Shares · 124,000 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:00 UTC |
DUNCAN BARBARA GAYLEDirector
|
GrantOption to purchase Ordinary Shares · Derivative | 158,233 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-18-042319 · a4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,233 Underlying: Ordinary Shares · 158,233 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:07 UTC |
MOTT DAVID MDirector · 10% owner
|
GrantOption to purchase Ordinary Shares · Derivative | 187,330 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-18-039519 · doc4.xml · derivative · entry 1 MOTT DAVID M · CIK 0001219871 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,330 Underlying: Ordinary Shares · 187,330 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:01 UTC |
Alleva Lawrence MDirector
|
GrantOption to purchase Ordinary Shares · Derivative | 124,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-18-042323 · a4.xml · derivative · entry 1 Alleva Lawrence M · CIK 0001553053 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Ordinary Shares · 124,000 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:05 UTC |
Behbahani AliDirector
|
GrantOption to purchase Ordinary Shares · Derivative | 154,809 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-18-039517 · doc4.xml · derivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,809 Underlying: Ordinary Shares · 154,809 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:00 UTC |
Sigal Charles ElliottDirector
|
GrantOption to purchase Ordinary Shares · Derivative | 154,809 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-18-042320 · a4.xml · derivative · entry 1 Sigal Charles Elliott · CIK 0001661908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,809 Underlying: Ordinary Shares · 154,809 shares Expires 2028-06-22 F1 · derivative.exercise_price: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 06, 2018 Filed Jun 6, 2018 22:10 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP V LLCDirector
|
SaleAmerican Depositary Shares representing Ordinary Shares | 1,600 | $13.49 | $21,584.00 |
DisclosureSEC source: 0000947871-18-000492 · ss95078_4.xml · nonDerivative · entry 2 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP V LLC · CIK 0001615374 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,901,310 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per share, of the Issuer. OrbiMed Private Investments V, LP ("OPI V") is the holder of record of the securities reported on this Form 4. OPI V's holdings consist of 25,408,300 ordinary shares held directly, and 666,593 ADSs representing 3,999,558 ordinary shares. Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $13.49 to $13.50 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. F5 · ownership.nature: This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Peter A. Thompson, a Private Equity Partner of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 06, 2018 Filed Jun 6, 2018 22:16 UTC |
Thompson Peter A.Director
|
SaleAmerican Depositary Shares representing Ordinary Shares | 1,600 | $13.49 | $21,584.00 |
DisclosureSEC source: 0000947871-18-000493 · ss95079_4.xml · nonDerivative · entry 2 Thompson Peter A. · CIK 0001357522 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,901,310 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per share, of the Issuer. OrbiMed Private Investments V, LP ("OPI V") is the holder of record of the securities reported on this Form 4. OPI V's holdings consist of 25,408,300 ordinary shares held directly, and 666,593 ADSs representing 3,999,558 ordinary shares. Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $13.49 to $13.50 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is a Private Equity Partner of Advisors. F5 · ownership.nature: Each of GP V, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 22:10 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP V LLCDirector
|
SaleAmerican Depositary Shares representing Ordinary Shares | 17,100 | $13.57 | $232,047.00 |
DisclosureSEC source: 0000947871-18-000492 · ss95078_4.xml · nonDerivative · entry 1 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP V LLC · CIK 0001615374 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,902,910 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per share, of the Issuer. OrbiMed Private Investments V, LP ("OPI V") is the holder of record of the securities reported on this Form 4. OPI V's holdings consist of 25,408,300 ordinary shares held directly, and 666,593 ADSs representing 3,999,558 ordinary shares. Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $13.50 to $13.69 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. F5 · ownership.nature: This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Peter A. Thompson, a Private Equity Partner of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 22:16 UTC |
Thompson Peter A.Director
|
SaleAmerican Depositary Shares representing Ordinary Shares | 17,100 | $13.57 | $232,047.00 |
DisclosureSEC source: 0000947871-18-000493 · ss95079_4.xml · nonDerivative · entry 1 Thompson Peter A. · CIK 0001357522 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,902,910 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per share, of the Issuer. OrbiMed Private Investments V, LP ("OPI V") is the holder of record of the securities reported on this Form 4. OPI V's holdings consist of 25,408,300 ordinary shares held directly, and 666,593 ADSs representing 3,999,558 ordinary shares. Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F2 · price: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $13.50 to $13.69 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is a Private Equity Partner of Advisors. F5 · ownership.nature: Each of GP V, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 21:25 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP V LLCDirector
|
SaleAmerican Depositary Shares representing Ordinary Shares | 50,000 | $13.49 | $674,500.00 |
DisclosureSEC source: 0000947871-18-000482 · ss94361_4.xml · nonDerivative · entry 2 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP V LLC · CIK 0001615374 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,920,010 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per share, of the Issuer. OrbiMed Private Investments V, LP ("OPI V") is the holder of record of the securities reported on this Form 4. OPI V's holdings consist of 25,408,300 ordinary shares held directly, and 685,293 ADSs representing 4,111,758 ordinary shares. Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $13.49 to $13.52 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. F5 · ownership.nature: This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Peter A. Thompson, a Private Equity Partner of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 21:27 UTC |
Thompson Peter A.Director
|
SaleAmerican Depositary Shares representing Ordinary Shares | 50,000 | $13.49 | $674,500.00 |
DisclosureSEC source: 0000947871-18-000483 · ss94359_4.xml · nonDerivative · entry 2 Thompson Peter A. · CIK 0001357522 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,920,010 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per share, of the Issuer. OrbiMed Private Investments V, LP ("OPI V") is the holder of record of the securities reported on this Form 4. OPI V's holdings consist of 25,408,300 ordinary shares held directly, and 685,293 ADSs representing 4,111,758 ordinary shares. Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $13.49 to $13.52 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. F4 · ownership.nature: These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is a Private Equity Partner of Advisors. F5 · ownership.nature: Each of GP V, Advisors, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.